Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851423 | 1.00 | STAT3 (0.32) | STAT3PTPN1 | |
| SCHEMBL15369586 | 0.85 | — | — | |
| SCHEMBL4160971 | 0.81 | STAT3 (0.32) | STAT3 | |
| SCHEMBL10181208 | 0.78 | STAT3 (0.33) | STAT3 | |
| SCHEMBL9960292 | 0.78 | STAT3 (0.33) | STAT3 | |
| SCHEMBL4330110 | 0.77 | — | — | |
| SCHEMBL18516998 | 0.75 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL15369604 | 0.74 | — | — | |
| SCHEMBL4162114 | 0.72 | — | — | |
| SCHEMBL13852409 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| EP-2655373-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013076236-A1 | PROCESS FOR PREPARING AN ANTIVIRAL DRUG AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2013-05-30 | — | — | WO | disclosed |
| EP-2474548-A1 | Preparation process of an antiviral drug and intermediates thereof | Esteve Química, S.A. (ES) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012085209-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | Esteve Química, S.A. (ES) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296558-A1 | PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF | TYMS, TPMT, TRDMT1 | STAT3 3361/4885PTPN1 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.